277 related articles for article (PubMed ID: 10993031)
41. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy.
Hall GM; Spector TD; Delmas PD
Arthritis Rheum; 1995 Jul; 38(7):902-6. PubMed ID: 7612039
[TBL] [Abstract][Full Text] [Related]
42. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density.
Chesnut CH; Bell NH; Clark GS; Drinkwater BL; English SC; Johnson CC; Notelovitz M; Rosen C; Cain DF; Flessland KA; Mallinak NJ
Am J Med; 1997 Jan; 102(1):29-37. PubMed ID: 9209198
[TBL] [Abstract][Full Text] [Related]
43. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.
Weinstein RS; Parfitt AM; Marcus R; Greenwald M; Crans G; Muchmore DB
Osteoporos Int; 2003 Oct; 14(10):814-22. PubMed ID: 14610642
[TBL] [Abstract][Full Text] [Related]
44. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial.
Grey AB; Stapleton JP; Evans MC; Tatnell MA; Reid IR
Ann Intern Med; 1996 Sep; 125(5):360-8. PubMed ID: 8702086
[TBL] [Abstract][Full Text] [Related]
45. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group.
Weiss SR; Ellman H; Dolker M
Obstet Gynecol; 1999 Sep; 94(3):330-6. PubMed ID: 10472854
[TBL] [Abstract][Full Text] [Related]
46. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
[TBL] [Abstract][Full Text] [Related]
47. New aspects of postmenopausal osteoporosis treatment with micronized estradiol and progesterone.
von Mach-Szczypiński J; Stanosz S; Kościuszkiewicz J; Safranow K
Ginekol Pol; 2016; 87(11):739-744. PubMed ID: 27958631
[TBL] [Abstract][Full Text] [Related]
48. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial.
Ettinger B; Ensrud KE; Wallace R; Johnson KC; Cummings SR; Yankov V; Vittinghoff E; Grady D
Obstet Gynecol; 2004 Sep; 104(3):443-51. PubMed ID: 15339752
[TBL] [Abstract][Full Text] [Related]
49. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
50. Oral weekly ibandronate prevents bone loss in postmenopausal women.
Tankó LB; Felsenberg D; Czerwiński E; Burdeska A; Jonkanski I; Hughes C; Christiansen C;
J Intern Med; 2003 Aug; 254(2):159-67. PubMed ID: 12859697
[TBL] [Abstract][Full Text] [Related]
51. Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate.
Al-Azzawi F; Lees B; Thompson J; Stevenson JC
Menopause; 2005; 12(3):331-9. PubMed ID: 15879923
[TBL] [Abstract][Full Text] [Related]
52. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
[TBL] [Abstract][Full Text] [Related]
53. Osteoporosis prevention clinical study program.
Delmas P; Gimona A
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S39-45. PubMed ID: 8732473
[TBL] [Abstract][Full Text] [Related]
54. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
55. Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis.
Palomba S; Orio F; Colao A; di Carlo C; Sena T; Lombardi G; Zullo F; Mastrantonio P
J Clin Endocrinol Metab; 2002 Apr; 87(4):1502-8. PubMed ID: 11932272
[TBL] [Abstract][Full Text] [Related]
56. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women.
Rubinacci A; Peruzzi E; Modena AB; Zanardi E; Andrei B; De Leo V; Pansini FS; Quebe-Fehling E; de Palacios PI
Menopause; 2003; 10(3):241-9. PubMed ID: 12792297
[TBL] [Abstract][Full Text] [Related]
57. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
Harris ST; Eriksen EF; Davidson M; Ettinger MP; Moffett AH; Baylink DJ; Crusan CE; Chines AA
J Clin Endocrinol Metab; 2001 May; 86(5):1890-7. PubMed ID: 11344179
[TBL] [Abstract][Full Text] [Related]
58. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.
Delmas PD; Pornel B; Felsenberg D; Stakkestad JA; Radowicki S; Garnero P; Hardy P; Dain MP; Petitier B;
Am J Obstet Gynecol; 2001 Jan; 184(2):32-40. PubMed ID: 11174476
[TBL] [Abstract][Full Text] [Related]
59. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women.
Salmen T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Pallonen H; Saarikoski S; Honkanen R; Mäenpää PH
Ann Med; 2003; 35(4):282-8. PubMed ID: 12846271
[TBL] [Abstract][Full Text] [Related]
60. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
